Startseite>>Signaling Pathways>> Microbiology & Virology>> Reverse Transcriptase>>Emtricitabine S-oxide

Emtricitabine S-oxide

Katalog-Nr.GC43600

Emtricitabin-S-Oxid (Emtricitabin-Sulfoxid) ist ein Hauptabbauprodukt von Emtricitabin.

Products are for research use only. Not for human use. We do not sell to patients.

Emtricitabine S-oxide Chemische Struktur

Cas No.: 152128-77-3

Größe Preis Lagerbestand Menge
1mg
67,00 $
Auf Lager
5mg
302,00 $
Auf Lager
10mg
535,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Emtricitabine S-oxide (Emtricitabine sulfoxide) is a major degradation product of Emtricitabine. Emtricitabine is a potent nucleoside reverse transcriptase inhibitor used for the treatment of HIV infection.

Emtricitabine, an antiretroviral agent is used to evaluate degradation pathways under different stress conditions in order to identify degradation products as prescribed by ICH guidelines. Emtricitabine degrades over 51%, 13% and 53% during acid, base and oxidative degradation respectively followed by formation of three major degradation products (Degradant-I to Degradant-III)[1].

References:
[1]. A Prakash, et al. Forced degradation study of emtricitabine for evaluation of genotoxic impurity in active pharmaceutical ingredient's (API) shelf life. World Journal of Pharmacy and Pharmaceutical Sciences (2015), 4(7), 1909-1919.

Bewertungen

Review for Emtricitabine S-oxide

Average Rating: 5 ★★★★★ (Based on Reviews and 17 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Emtricitabine S-oxide

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.